menu
    • menu

    Company profile for EicOsis

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EicOsis is devel​oping a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and companion animals. ​EicOsis is developing inhibitors to a the soluble epoxide hydrolase, a key regulatory enzyme involved in the metabolism of fatty acids, to treat unmet medical needs in human and animals. sEH inhibitors treat pain by stabilizing natural analgesic and anti-inflammatory mediat...
    EicOsis is devel​oping a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and companion animals. ​EicOsis is developing inhibitors to a the soluble epoxide hydrolase, a key regulatory enzyme involved in the metabolism of fatty acids, to treat unmet medical needs in human and animals. sEH inhibitors treat pain by stabilizing natural analgesic and anti-inflammatory mediators.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EicOsisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    140 B Street, Suite 5, Number 346 Davis, CA 95616
    Telephone
    Telephone
    916-555-121
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eicosis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eicosis/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/eicosis

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EicOsis Initiates Phase 1b Clinical Trial of EC5026
    EicOsis Initiates Phase 1b Clinical Trial of EC5026

    30 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eicosis-initiates-phase-1b-clinical-trial-of-ec5026-302047230.html

    PR NEWSWIRE
    30 Jan 2024
    Share Share
    EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026
    EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026

    17 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/eicosis-successfully-completes-phase-1a-clinical-trial-of-ec5026-301174243.html

    PRNEWSWIRE
    17 Nov 2020
    Share Share
    EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain
    EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain

    09 Apr 2020

    // ADVFN

    https://uk.advfn.com/stock-market/stock-news/82204527/eicosis-ec5026-granted-fast-track-designation-by-f

    ADVFN
    09 Apr 2020
    Share Share
    EicOsis Announces FDA Acceptance of IND Application for EC5026
    EicOsis Announces FDA Acceptance of IND Application for EC5026

    10 Oct 2019

    // PRNEWS WIRE

    https://www.prnewswire.com/news-releases/eicosis-announces-fda-acceptance-of-ind-application-for-ec5026-the-first-soluble-epoxide-hydrolase-inhibitor-to-treat-pain-300935138.html

    PRNEWS WIRE
    10 Oct 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search